Portola Pharmaceuticals, Inc. (PTLA)


Stock Price Forecast

June 26, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Portola Pharmaceuticals, Inc. chart...

About the Company

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Sector

Health Technology

Industry

Pharmaceuticals: Other

Employees

408

CEO

J. Scott Garland

Exchange

NASDAQ

Website

http://www.portola.com

$121M

Total Revenue

408

Employees

$1B

Market Capitalization

-4.77

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $PTLA News

Dighton police chief on leave, officer suspended as they face insider trading charges

9mon ago, source: Hosted on MSN

Prosecutors allege that Dupont provided information on an upcoming acquisition of another company, Portola Pharmaceuticals, Inc. to Cronin before the information was public. Cronin, prosecutors ...

All Eyes Are on Madrigal Pharmaceuticals as FDA’s Decision Draws Closer

16d ago, source: MONTCO.Today on MSN

Later this week, the U.S. Food and Drug Administration is expected to make a decision on Madrigal Pharmaceuticals’ ...

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

1mon ago, source: Yahoo Finance

She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated ...

Madrigal Pharma CFO Alex Howarth Quits, Mardi Dier Named Replacement

29d ago, source: Nasdaq

Dier has more than 20 years of experience in executive financial leadership roles and was the finance chief in companies like Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin ...

Madrigal Pharmaceuticals names new CFO amid growth phase

29d ago, source: Investing

Dier's extensive background includes serving as CFO at several companies, including Portola Pharmaceuticals, Ultragenyx Pharmaceutical (NASDAQ:RARE), Inc., and Acelyrin, Inc. During her tenure at ...

MRNS Marinus Pharmaceuticals, Inc.

15h ago, source: Seeking Alpha

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure ...

ELDN Eledon Pharmaceuticals, Inc.

6d ago, source: Seeking Alpha

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to ...

Merrimack Pharmaceuticals Inc MACK

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

29d ago, source: Finanznachrichten

She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated ...

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

1mon ago, source: Yahoo Finance

She has held Chief Financial Officer positions at Portola Pharmaceuticals, Ultragenyx Pharmaceutical, Inc., and Acelyrin, Inc. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Mardi has an ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...